Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-DOTATATE PET/CT for Neuroendocrine Tumor Evaluation
NCT04041882Phase 1Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2014
- Primary completion
- Dec 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of gallium ga 68 dotatate in Neuroendocrine Neoplasm (NEN), sponsored by Peking Union Medical College Hospital. Primary endpoints: Maximum Standardized Uptake Value at 3 years and Diagnostic value at 3 years. Status: unknown.
02
Drugs
gallium ga 68 dotatate
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT04041882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04041882.